
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific demonstrates a strong growth outlook, with the Watchman product line projected to achieve a compound annual growth rate (CAGR) of 20% over the long-range plan (LRP), supported by potential positive data from the Champion trial. The company's electrophysiology (EP) revenue is expected to rise from an estimated $3.3 billion in 2025 to approximately $6 billion by 2028, reflecting a CAGR of about 22%, indicating robust demand for its innovations. Additionally, Boston Scientific anticipates continued mid-teens revenue growth from the Chinese market, bolstering its international sales, which already constitute roughly 36% of total revenue.
Bears say
Boston Scientific faces several fundamental challenges that contribute to a negative outlook on its stock. Key risks include potential slowdowns in innovation, increased competition in core markets, and uncertainty surrounding the success of ongoing and future product launches, which could adversely affect revenue growth. Additionally, the company may encounter integration risks from mergers and acquisitions, difficulties in managing existing and future debt, and challenges in expanding internationally, further exacerbated by the possibility of litigation risks.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares